GW Pharmaceuticals PLC (NASDAQ:GWPH) to Release Earnings on Monday
GW Pharmaceuticals PLC (NASDAQ:GWPH) will be issuing its quarterly earnings data after the market closes on Monday, August 7th. Analysts expect the company to announce earnings of ($1.73) per share for the quarter.
GW Pharmaceuticals PLC (NASDAQ:GWPH) last issued its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.50) by $0.20. GW Pharmaceuticals PLC had a negative return on equity of 22.81% and a negative net margin of 1,021.38%. The firm had revenue of $2.04 million during the quarter, compared to the consensus estimate of $2.07 million. During the same period last year, the firm posted ($0.06) earnings per share. The company’s revenue for the quarter was down 23.0% compared to the same quarter last year. On average, analysts expect GW Pharmaceuticals PLC to post $-5.67 EPS for the current fiscal year and $-4.81 EPS for the next fiscal year.
Shares of GW Pharmaceuticals PLC (NASDAQ GWPH) opened at 117.61 on Friday. The stock has a 50 day moving average price of $105.72 and a 200 day moving average price of $113.95. GW Pharmaceuticals PLC has a one year low of $79.62 and a one year high of $137.88. The company’s market capitalization is $2.98 billion.
TRADEMARK VIOLATION WARNING: This news story was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/08/06/gw-pharmaceuticals-plc-nasdaqgwph-to-release-earnings-on-monday.html.
A number of research analysts recently weighed in on GWPH shares. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $208.00 price target on shares of GW Pharmaceuticals PLC in a research note on Tuesday, May 9th. Maxim Group reaffirmed a “buy” rating and issued a $135.00 price target on shares of GW Pharmaceuticals PLC in a research note on Thursday, May 25th. Zacks Investment Research lowered shares of GW Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a research note on Monday, May 15th. BidaskClub raised shares of GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a research note on Wednesday, June 21st. Finally, ValuEngine raised shares of GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a research note on Wednesday, June 21st. Four research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. GW Pharmaceuticals PLC presently has a consensus rating of “Buy” and an average price target of $156.38.
About GW Pharmaceuticals PLC
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).
Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.